GGrantIndex
← Search

CORE--GENOMICS

$0P30FY2002CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07456436Trial NCT07339254Trial NCT07332312Trial NCT07312162Trial NCT07306338Trial NCT07279571Trial NCT07276048Trial NCT07259304Trial NCT07229443Trial NCT07186699Trial NCT07162194Trial NCT07082257Trial NCT07076147Trial NCT06500169Trial NCT06422455Trial NCT06420219Trial NCT06374251Trial NCT06338657Trial NCT06336928Trial NCT06336902Trial NCT06297265Trial NCT06191575Trial NCT06171607Trial NCT06132087Trial NCT06128525Trial NCT06067295Trial NCT06063928Trial NCT06063486Trial NCT06060873Trial NCT05989828Trial NCT05791448Trial NCT05786664Trial NCT05516485Trial NCT05514990Trial NCT05462561Trial NCT05340309Trial NCT04981834Trial NCT04941430Trial NCT04927559Trial NCT04832763Trial NCT04830735Trial NCT04752267Trial NCT04387084Trial NCT04387071Trial NCT04373044Trial NCT04318028Trial NCT04315701Trial NCT04162678Trial NCT03971266Trial NCT03921047Trial NCT03858205Trial NCT03789773Trial NCT03739801Trial NCT03698162Trial NCT03657641Trial NCT03594448Trial NCT03576963Trial NCT03568292Trial NCT03568266Trial NCT03563651Trial NCT03563352Trial NCT03552796Trial NCT03537690Trial NCT03519984Trial NCT03514927Trial NCT03492801Trial NCT03485794Trial NCT03412370Trial NCT03408561Trial NCT03353896Trial NCT03348137Trial NCT03344211Trial NCT03330821Trial NCT03300609Trial NCT03300401Trial NCT03284346Trial NCT03267680Trial NCT03257761Trial NCT03238664Trial NCT03234556Trial NCT03207854Trial NCT03176979Trial NCT03146871Trial NCT03137706Trial NCT03120390Trial NCT03111823Trial NCT03098277Trial NCT03092856Trial NCT03091842Trial NCT03091816Trial NCT03091803Trial NCT03057639Trial NCT03049618Trial NCT03042897Trial NCT02978846Trial NCT02970617Trial NCT02970045Trial NCT02968680Trial NCT02967380Trial NCT02960308

Abstract

The Genomics Core Facility is a newly proposed core that will perform high throughput analyses of genetic (polymorphism/mutations) and epigenetic various (DNA methylation) that underlie predisposition and progression to cancer. The Core will use the latest technology to evaluate primarily genetic variations for association studies using single nucleotide polymorphisms (SNPs). SNPs represent the most commonly occurring DNA sequence variations in the human genome and within several years these polymorphisms will be present at a density of 1 every 1-2 kb. A dense set of these markers can be used to identify genetic factors associated with complex disease traits. These analyses can be performed to investigate germline genetic changes giving rise to hereditary or familial cancer and to investigate somatic genetic changes that are hallmarks of clonal expansion in tumors. In addition, the Core will provide methods for evaluating the genetic the inheritance of information on the basis of epigenetics. DNA methylation is the only epigenetic mark preserved in genomic DNA isolated from tumors or biopsies. The large number of studies documenting associations between methylation patterns and gene expression suggest that the DNA methylation pattern of a cell may represent a rough blueprint for the expression profile of that cell. In addition, the use of genetically modified mice as models for cancer and tumorigenesis will be supported by the Genomics Core Facility by genotyping mouse progeny in conjunction with the Transgenic Core Facility to follow genetic markers during mating. The new Core Facility will utilize expertise in epidemiologic/population studies and DNA methylation present within the Cancer Center projects and providing resources for future initiatives. Finally, it is envisioned that future development in gene chip array technology will be utilized to assess multiple SNPs simultaneously. Analysis of such DNA SNP arrays will be performed by the Microarray Core Facility; however DNA and template preparations for this purpose will still be performed by the Genomics Core Facility.

View original record on NIH RePORTER →